Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil

DOI: 10.1016/j.ejphar.2004.09.005
European Journal of Pharmacology, 2004, 502, 163-7.

#	Paper	IF	Citations
27	A three-part study to investigate the incidence and potential etiologies of tadalafil-associated back pain or myalgia. *International Journal of Impotence Research*, **2005**, 17, 455-61	2.3	12
26	The therapeutic dilemma: how to use tadalafil. *Journal of Developmental and Physical Disabilities*, **2005**, 28 Suppl 2, 74-80		36
25	The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. *Journal of the American College of Cardiology*, **2005**, 46, 678-87	15.1	27
24	Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective. *Urology*, **2006**, 68, 47-60	1.6	55
23	A QSAR model of HERG binding using a large, diverse, and internally consistent training set. *Chemical Biology and Drug Design*, **2006**, 67, 284-96	2.9	65
22	Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. *International Journal of Impotence Research*, **2007**, 19, 281-95	2.3	33
21	Effects of phosphodiesterase (PDE) inhibitors on human ether-a-go-go related gene (hERG) channel activity. *Journal of Applied Toxicology*, **2007**, 27, 78-85	4.1	7
20	Identification of "toxicophoric" features for predicting drug-induced QT interval prolongation. *European Journal of Medicinal Chemistry*, **2008**, 43, 2479-88	6.8	13
19	Cardiac sodium channels and inherited electrophysiologic disorders: a pharmacogenetic overview. *Expert Opinion on Pharmacotherapy*, **2008**, 9, 537-49	4	12
18	Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugsTcardiotoxic properties. *Journal of Applied Toxicology*, **2009**, 29, 183-206	4.1	77
17	Quantitative structure-activity relationship models for predicting biological properties, developed by combining structure- and ligand-based approaches: an application to the human ether-a-go-go-related gene potassium channel inhibition. *Chemical Biology and Drug Design*, **2009**, 74, 416-33	2.9	6
16	The use of beat-to-beat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil. *Clinical Pharmacology and Therapeutics*, **2011**, 90, 449-54	6.1	11
15	Phosphodiesterase inhibitors, congestive heart failure, and sudden death: time for re-evaluation. *Congestive Heart Failure*, **2012**, 18, 229-33		13
14	Does your model weigh the same as a duck?. *Journal of Computer-Aided Molecular Design*, **2012**, 26, 57-67	4.2	20
13	Predicting the potency of hERG K+ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models. *Journal of Molecular Modeling*, **2012**, 18, 1023-36	2	22
12	Combining structure- and ligand-based approaches for studies of interactions between different conformations of the hERG K+ channel pore and known ligands. *Journal of Molecular Graphics and Modelling*, **2013**, 46, 93-104	2.8	14
11	Computational investigations of hERG channel blockers: New insights and current predictive models. *Advanced Drug Delivery Reviews*, **2015**, 86, 72-82	18.5	53

10	Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2017**, 32, 311-330	5.6	20
9	In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors. *Journal of Biomolecular Structure and Dynamics*, **2017**, 35, 2830-2852	3.6	1
8	Computational Approaches in the Development of Phosphodiesterase Inhibitors. **2017**,		
7	Long-term effect of sildenafil on echocardiographic parameters in dogs with asymptomatic myxomatous mitral valve degeneration. *Journal of Veterinary Medical Science*, **2017**, 79, 788-794	1.1	4
6	Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?. *Heart*, **2018**, 104, 1244-1250	5.1	43
5	Apelin shorten QT interval by inhibiting Kir2.1/I via a PI3K way in acute myocardial infarction. *Biochemical and Biophysical Research Communications*, **2019**, 517, 272-277	3.4	3
4	Various subtypes of phosphodiesterase inhibitors differentially regulate pulmonary vein and sinoatrial node electrical activities. *Experimental and Therapeutic Medicine*, **2020**, 19, 2773-2782	2.1	1
3	Cardiomyocytes Derived from Human Induced Pluripotent Stem Cells: An In-Vitro Model to Predict Cardiac Effects of Drugs. *Journal of Biomedical Science and Engineering*, **2017**, 10, 527-549	0.7	3
2	In silico Analysis on hERG Channel Blocking Effect of a Series of T-type Calcium Channel Blockers. *Bulletin of the Korean Chemical Society*, **2011**, 32, 251-262	1.2	
1	Combination of Sildenafil and Ba at a Low Concentration Show a Significant Synergistic Inhibition of Inward Rectifier Potassium Current Resulting in Action Potential Prolongation.. *Frontiers in Pharmacology*, **2022**, 13, 829952	5.6	0